|
|
|
Stem Cell Related Patent Number US5850004
| Title: | Transgenic mouse deficient in inducible nitric oxide synthase | | Inventors: | MacMicking, John; New York, NY, USA
Nathan, Carl; Larchmont, NY, USA
Mudgett, John S.; Scotch Plains, NJ, USA | | Summary: | This invention introduces a novel transgenic nonhuman mammal, the somatic and germ cells of which are comprised of a homozygous disrupted inducible nitric oxide synthase gene. Described herein is an inducible nitric oxide synthase (iNOS)-deficient transgenic mouse, including novel replacement vectors designed for the disruption of the iNOS gene, embryonic stem cells which are singly allelic relative to the deficient iNOS locus, a host cell line or cell clone carrying a congenitally altered iNOS gene, and methods of producing such a transgenic mouse. Claims of the invention include the demonstration of an increased susceptibility to bacterial or viral infection in the mouse, and a decrease in susceptibility to sepsis as compared to a wild type mouse. Therapeutic applications include the use of such iNOS-deficient transgenic mice in the evaluation of their susceptibility to infectious or tumorigenic challenge, autoimmunity, septic shock, inflammatory and allergic diseases, for models in the treatment of such conditions in humans. | | Abstract: | The present invention provides an inducible nitric oxide synthase (iNOS)-deficient transgenic mouse, novel replacement vectors designed for the disruption of the iNOS gene, embryonic stem (ES) cells which are singly allelic relative to the deficient iNOS locus, a host cell line or cell clone carrying a congenitally altered iNOS gene, and a method of producing such a transgenic mouse. The iNOS-deficient transgenic mice can be used to evaluate and/or test their susceptibility to infectious or tumorigenic challenge, autoimmunity, septic shock and inflammatory and allergic diseases. | | US Patent Website: | Click Here for Full Text of Patent | | Title Number: | US5850004 | | Application Number: | US1997000808191 | | Date Filed: | 28/02/1997 | | Date Published: | 15/12/1998 | | Assignee: | Cornell Research Foundation, Inc., Ithaca, NY, USA
Merck and Co., Inc., Rahway, NJ, USA |
|
|
